From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

Title:From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

Volume: 19 Issue: 29

Author(s): Samuele De Minicis, Chris Day and Gianluca Svegliati-Baroni

Affiliation:

Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.

Abstract: NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.

Cite this article as:

De Minicis Samuele, Day Chris and Svegliati-Baroni Gianluca, From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290006